drugset / Trial / NCT05042245

Summary

This is a multicenter, randomized, double-blind, double-dummy, and positive control clinic trial which explores the efficacy and safety of ornithine aspartate granules in the treatment of non-alcoholic fatty liver disease against silymarin capsules. The hypothesis is that the ornithine aspartate granules have similar or better efficacy than the silymarin capsules.

Timeline

Start
2019-07-23
Primary completion
2022-12-18
Completion
2022-12-20

Drugs

EvaluationDrugModalityDoseRoute
Subject L-ornithine L-aspartate Other / unclassified 3 g Oral
Comparator Silymarin Traditional medicine (herbal / TCM) 140 mg Oral

Indications